Omrix fully enrolls phase 3 trial of Thrombin

New York, June 26 - Omrix Biopharmaceuticals, Inc. said it has completed enrollment of its phase 3 pivotal trial of Thrombin.

A total of 304 patients are included in the study, which is comparing thrombin topical (human) to bovine thrombin in achieving intra-operative hemostasis - control of bleeding - during cardiovascular, neurologic (spine) and general surgery procedures.

The target indication is general hemostasis.

Thrombin is derived from human plasma and is designed to provide effective control of bleeding without the risk of adverse reactions associated with bovine-sourced hemostats.

Currently, the only stand-alone thrombin product available in the United States is a bovine-based lyophilized product.

Omrix is a New York-based biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.